^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Regimen: (cisplatin + gemcitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Other acceptable first-line combination chemotherapy options recommended by NCCN include:...2) gemcitabine/cisplatin...